Israeli biotechnology company Polyrizon Ltd. (NASDAQ: PLRZ) has recently completed a registered direct offering and private placement with a sole institutional investor. The offerings included the issuance of Ordinary Shares and pre-funded warrants in the registered direct offering, as well as pre-funded and investor warrants in the private placement. These transactions generated total gross proceeds of around $3.5 million for the Company. The deals were finalized on April 8, 2026, marking a significant milestone for Polyrizon Ltd.